Large volume leukapheresis (LVL) reduces the number of procedures required to obtain adequate peripheral blood progenitor cells (PBPCs) for autologous hematopoietic reconstitution. LVL involves the processing of >15 L or 5 patient blood volumes using high flow rates. We report our experience with LV
Collection of peripheral progenitor cells in paediatric patients with a new programme for the collection of mononuclear cells
β Scribed by R. Moog; O. Basu; B. Kremens
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 71 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
When harvesting peripheral progenitor cells (PPC) in children, the special situation of their circulatory system has to be taken into account. Therefore, extracorporeal blood volume and product volume should be small to avoid side effects. Nine children (age 2β14 years, weight 12.8β58.5 kg) with malignancies underwent 10 PPC collections with the MNC programme of the Amicus blood cell separator. The disposable kit was primed with red blood cells (RBCs) or human albumin to avoid circulatory side effects. The children were monitored for blood pressure and heart rate during the whole apheresis procedure. A median blood volume of 4,577 ml (range 3,536β8,596 ml) was processed in a separation time of 270 min (range 176β331 min). The median product weight was 81 g (range 53β107 g) and the yield of CD 34 antigen expressing cells was 12.5 Γ 10^6^/kg body weight (range 1.8β26 Γ 10^6^/kg body weight). Only one child had to undergo a second apheresis to collect the desired transplantation dose. The median platelet contamination of the product was 0.32 Γ 10^11^ (0.13β0.85 Γ 10^11^). No circulatory side effects were observed. Blood flow alarms occurred in seven of ten aphereses and one collection had to be terminated due to insufficient flow. PPC can be efficiently collected in children with the MNC programme without circulatory side effects. The platelet contamination of the product was low due to the elutriation principle of the collection process, thereby avoiding thrombocytopenic bleeding episodes in the patients. J. Clin. Apheresis, 18:111β114, 2003. Β© 2003 WileyβLiss, Inc.
π SIMILAR VOLUMES
Central venous catheters are used frequently in large-volume leukapheresis to provide high flow rates for peripheral blood progenitor cell (PBPC) collection. In a retrospective study, we evaluated the safety and efficacy of short-term use of large-bore femoral venous catheters for the collection of
In order to investigate what is the best single parameter to predict the leukapheretic yield of circulating CD34+ progenitor cells, we retrospectively analyzed data from 68 patients with hematological malignancies who underwent mobilizing therapy. Three main parameters were monitored: total white bl
The aim of the present study was to clinically evaluate the blood cell separator AS.TEC 204. One hundred fifteen platelet collections were carried out with the dual or single needle procedure. Platelet yield was 3.21 Β± 0.80 Γ 10 11 (mean Β± standard deviation) and 59.1% of the collections showed plat
Peripheral blood mononuclear cells (PBMC) were collected as a byproduct of plateletpheresis of normal blood cell donors using modifications to standard automated protocols on either the CS-3000 or Spectra blood cell separator machine. Comparison of the PBMC products obtained showed X & SD WBC yields
Information on the safety of mobilization and collection of peripheral blood progenitor cells (PBPC) in patients with advanced coronary heart disease (CHD) is limited. We report herein our early experience with patients participating in a Phase I trial of injection of autologous CD 34(+) cells into